

Table SI. Distribution of depression, anxiety and stressful life events among dermatological patients

| Diagnosis (if valid $n > 15$) | Any anxiety (HADS ≥ 8) n (%) | Clinical anxiety (HADS ≥ 11) n (%) | Any depression (HADS ≥ 8) n (%) | Clinical depression (HADS ≥ 11) n (%) | Stressful events last 6 months n (%) |
|---|--|--|---|---|--|
| Healthy controls ($n=218$) | 32/216 (14.8) | 8/216 (3.7) | 12/216 (5.6) | 2/216 (0.9) | 44/215 (20.5) |
| All patients ($n=577$) | 144/532 (27.1)* | 69/532 (13)* | 71/532 (13.3)* | 31/532 (5.8)* | 162/538 (30.1)* |
| Chronic recurrent skin diseases ($n=400$) | 111/372 (29.8)* | 54/372 (14.5)* | 61/372 (16.4)* | 28/372 (7.5)* | 121/379 (31.9)* |
| Tumours, benign, malignant and precancerous ($n=168$) | 26/151 (17.2) | 10/151 (6.6) | 8/151 (5.3) | 2/151 (1.3) | 36/151 (23.8) |
| Psoriasis ($n=121$) | 44/113 (38.9)* | 25/113 (22.1)* | 25/112 (22.3)* | 12/112 (10.7)* | 40/116 (34.5)* |
| Urticaria, pruritus, prurigo ($n=26$) | 8/24 (33.3)** | 6/24 (25)* | 7/24 (29.2)* | 2/24 (8.3) | 10/25 (40)** |
| Autoimmune disease ^a ($n=26$) | 8/25 (32)** | 3/25 (12) | 6/25 (24)** | 2/25 (8) | 9/25 (36) |
| Atopic dermatitis ($n=29$) | 8/28 (28.6) | 2/28 (7.1) | 3/28 (10.7) | 3/28 (10.7)* | 11/29 (37.9)** |
| Acne, rosacea, other facial ($n=64$) | 16/62 (25.8**) | 5/62 (8.1) | 5/62 (8.1) | 2/62 (3.2) | 14/61 (23) |
| Pustulosis palmoplantaris ($n=17$) | 4/16 (25) | 2/16 (12.5) | 2/15 (13.3) | 1/15 (6.7) | 3/15 (20) |
| Malignant melanoma ($n=21$) | 5/21 (23.8) | 4/21 (19)** | 2/21 (9.5) | 0/21 (0) | 10/20 (50)* |
| Eczemas and contact allergy ($n=39$) | 8/35 (22.9) | 4/35 (11.4) | 6/37 (16.2)** | 3/37 (8.1) | 10/38 (26.3) |
| Actinic keratosis ($n=50$) | 10/45 (22.2) | 4/45 (8.9) | 3/45 (6.7) | 0/45 (0) | 7/45 (15.6) |
| Hand eczema ($n=19$) | 4/18 (22.2) | 1/18 (5.6) | 2/18 (11.1) | 1/18 (5.6) | 6/18 (33.3) |
| Non-melanoma skin cancer ($n=61$) | 9/55 (16.4) | 1/55 (1.8) | 2/55 (3.6) | 1/55 (1.8) | 12/55 (21.8) |
| Naevi and benign tumours ($n=29$) | 1/24 (4.2) | 1/24 (4.2) | 1/24 (4.2) | 1/24 (4.2) | 5/25 (20) |

* $p < 0.01$, significant at 1% significance level compared with healthy controls using χ^2 test. ** $p < 0.05$, significant at 5% significance level compared with healthy controls using χ^2 test.

^aAutoimmune disease: connective tissue disease, vasculitis, autoimmune blistering.